Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.65 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.52 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.52 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610235 | 0.88 | ALDH1A1 (0.51) | KMOPLOD2PLOD3PLOD1LMNA | |
| SCHEMBL611101 | 0.85 | ALDH1A1 (0.62) | KMOPLOD2PLOD3PLOD1LMNA | |
| SCHEMBL13724478 | 0.84 | KMO (0.74) | KMOPLOD2PLOD3PLOD1LMNA | |
| SCHEMBL609036 | 0.83 | ALDH1A1 (0.60) | KMOLMNAAGXTALDH1A1KDM4E | |
| SCHEMBL610163 | 0.83 | ALDH1A1 (0.60) | KMOLMNAAGXTALDH1A1KDM4E | |
| SCHEMBL608471 | 0.83 | KMO (0.68) | KMOPLOD2PLOD3PLOD1LMNA | |
| SCHEMBL4770473 | 0.81 | ALDH1A1 (0.58) | LMNAPRKDCALDH1A1KDM4EMEN1 | |
| SCHEMBL15579368 | 0.81 | ADRB1 (0.58) | ALDH1A1MAPTHTTCYP1A2 | |
| SCHEMBL671894 | 0.80 | KMO (0.64) | KMOPLOD2PLOD3PLOD1LMNA | |
| SCHEMBL65857 | 0.79 | KMO (1.00) | KMOPLOD2PLOD3PLOD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | KMO 1041/4885PLOD2 3825/4885PLOD3 4328/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | KMO 634/4885PLOD2 3311/4885PLOD3 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.